Author/Authors :
Kaya، Hiroyasu نويسنده , , Nakamura، Shinobu نويسنده , , Okafuji، Kazuhiro نويسنده , , Terasaki، Yasushi نويسنده , , Maeno، Koji نويسنده , , Tanaka، Nobuyoshi نويسنده , , Ohtake، Shigeki نويسنده , , Matsuda، Tamotsu نويسنده ,
Abstract :
It has been reported that trisomy 14 is associated with myeloid malignancies, but a case with increased platelet count has also been reported. However, the clinical significance of trisomy 14 is still uncertain. We report a patient with trisomy 14 with thrombocytosis and a gradual increase in monocytosis. He was treated with hydroxyurea, cytarabine and aclarubicin in low doses and his quality of life was maintained for a period of about 1 year from blastic crisis. Hydroxyurea, cytarabine or aclarubicin in low doses may be the treatment of choice for trisomy 14 patients with respect to the patientsʹ quality of life.
